December 05, 2018
Program for Oncopeptides Capital Markets Day December 14th, 2018
Media
December 04, 2018
Nordic Nanovector: Additional preclinical studies with CD37-targeting radioimmunotherapies for B-cell malignancies presented at ASH
December 03, 2018
Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting
December 02, 2018
Nordic Nanovector: Single administration Betalutin® is effective and well-tolerated in R/R iNHL patients: 6 month follow-up data presented at ASH
December 02, 2018
Aprea Therapeutics Closes EUR 50 Million Financing
December 02, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego
December 01, 2018
Oncopeptides presents first interim data from the ongoing combination trial ANCHOR with melflufen at the 60th American Society of Hematology Meeting
November 30, 2018
US Court of Appeals denies Actavis’s petition for rehearing regarding validity of the Zubsolv® patent
November 30, 2018
Vicore Pharma’s Board of Directors has resolved on a directed share issue of around SEK 160 million to finance the continued development of the drug development programs VP01 and VP02
November 28, 2018
Targovax is invited to present at upcoming investor and industry conferences